Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Open access

Abstract

The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that Helicobacter pylori seropositivity was associated with a negative prognosis in patients amenable to ICI. In 97 patients with advanced melanoma treated with ICI, we assessed the impact of H. pylori on outcomes and microbiome composition. We performed H. pylori serology and profiled the fecal microbiome with metagenomics sequencing. Among the 97 patients, 22% were H. pylori positive (Pos). H. pylori Pos patients had a significantly shorter overall survival (p = .02) compared to H. pylori negative (Neg) patients. In addition, objective response rate and progression-free survival were decreased in H. pylori Pos patients. Metagenomics sequencing did not reveal any difference in diversity indexes between the H. pylori groups. At the taxa level, Eubacterium ventriosum, Mediterraneibacter (Ruminococcus) torques, and Dorea formicigenerans were increased in the H. pylori Pos group, while Alistipes finegoldii, Hungatella hathewayi and Blautia producta were over-represented in the H. pylori Neg group. In a second independent cohort of patients with NSCLC, diversity indexes were similar in both groups and Bacteroides xylanisolvens was increased in H. pylori Neg patients. Our results demonstrated that the negative impact of H. pylori on outcomes seem to be independent from the fecal microbiome composition. These findings warrant further validation and development of therapeutic strategies to eradicate H. pylori in immuno-oncology arena.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2022.2096535

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Association between the H. pylori seropositivity status and clinical outcomes in 97 patients with advanced melanoma. A. Stacked barplot between H. pylori seropositivity status in terms of ORR in 97 patients with advanced melanoma. CR; complete response. PR; partial response, SD; stable disease, PD; progressive disease analyzed using Chi-square test. B. Kaplan–Meier curve of overall survival in 97 patients with advanced melanoma. C. Kaplan–Meier curve of progression-free survival in 97 patients with advanced melanoma. D. Stacked barplot between H. pylori seropositivity status in terms of autoimmune toxicities in 97 patients with advanced melanoma.
Figure 1. Association between the H. pylori seropositivity status and clinical outcomes in 97 patients with advanced melanoma. A. Stacked barplot between H. pylori seropositivity status in terms of ORR in 97 patients with advanced melanoma. CR; complete response. PR; partial response, SD; stable disease, PD; progressive disease analyzed using Chi-square test. B. Kaplan–Meier curve of overall survival in 97 patients with advanced melanoma. C. Kaplan–Meier curve of progression-free survival in 97 patients with advanced melanoma. D. Stacked barplot between H. pylori seropositivity status in terms of autoimmune toxicities in 97 patients with advanced melanoma.CC BY-NC · PubMed Central
Figure 2. Association between the H. pylori seropositivity status and clinical outcomes in 78 patients with advanced melanoma treated with first-line ICI. A. Stacked barplot between H. pylori seropositivity status in terms of ORR in 78 patients with advanced melanoma treated with first-line ICI. CR; complete response. PR; partial response, SD; stable disease, PD; progressive disease analyzed using Chi-square test. B. Kaplan–Meier curve of overall survival in 78 patients with advanced melanoma treated with first-line ICI. C. Kaplan–Meier curve of progression-free survival in 78 patients with advanced melanoma treated with first-line ICI. D. Stacked barplot between H. pylori seropositivity status in terms of autoimmune toxicities in 78 patients with advanced melanoma treated with first-line.
Figure 2. Association between the H. pylori seropositivity status and clinical outcomes in 78 patients with advanced melanoma treated with first-line ICI. A. Stacked barplot between H. pylori seropositivity status in terms of ORR in 78 patients with advanced melanoma treated with first-line ICI. CR; complete response. PR; partial response, SD; stable disease, PD; progressive disease analyzed using Chi-square test. B. Kaplan–Meier curve of overall survival in 78 patients with advanced melanoma treated with first-line ICI. C. Kaplan–Meier curve of progression-free survival in 78 patients with advanced melanoma treated with first-line ICI. D. Stacked barplot between H. pylori seropositivity status in terms of autoimmune toxicities in 78 patients with advanced melanoma treated with first-line.CC BY-NC · PubMed Central
Figure 3. Gut microbiome composition for H. pylori Pos and H. pylori Neg patients in melanoma cohort. A. Alpha diversity of H. pylori Pos and H. pylori Neg patients (n = 43). The bold line represents the median. The bottom and top hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The top whisker extends from the hinge to the largest value no further than 1.5 * interquartile range from the hinge. B. Beta diversity for 43 patients with melanoma stratified by H. pylori seropositivity. C. Differential abundance analysis using LEfSe stratified by H. pylori status. Only species were displayed. Note that the presence of each bacterium on the LEfSe denotes statistical significance (p < .05). D. Relative abundance of Bifidobacterium longum between H. pylori Pos and H. pylori Neg patients. E. Relative abundance of Faecalibacterium prausnitzii between H. pylori Pos and H. pylori Neg patients.
Figure 3. Gut microbiome composition for H. pylori Pos and H. pylori Neg patients in melanoma cohort. A. Alpha diversity of H. pylori Pos and H. pylori Neg patients (n = 43). The bold line represents the median. The bottom and top hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The top whisker extends from the hinge to the largest value no further than 1.5 * interquartile range from the hinge. B. Beta diversity for 43 patients with melanoma stratified by H. pylori seropositivity. C. Differential abundance analysis using LEfSe stratified by H. pylori status. Only species were displayed. Note that the presence of each bacterium on the LEfSe denotes statistical significance (p < .05). D. Relative abundance of Bifidobacterium longum between H. pylori Pos and H. pylori Neg patients. E. Relative abundance of Faecalibacterium prausnitzii between H. pylori Pos and H. pylori Neg patients.CC BY-NC · PubMed Central
Figure 4. Gut microbiome composition for H. pylori Pos and H. pylori Neg patients in lung cohort. Alpha diversity of H. pylori Pos and H. pylori Neg NSCLC patients (n = 28). The bold line represents the median. The bottom and top hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The top whisker extends from the hinge to the largest value no further than 1.5 * interquartile range from the hinge. B. Beta diversity for 28 NSCLC patients stratified by H. pylori seropositivity. C. Differential abundance analysis using LEfSe stratified by H. pylori status. Only species were displayed. Note that the presence of each bacterium on the LEfSe denotes statistical significance (p < .05). D. Relative abundance of Akkermansia muciniphila between H. pylori Pos and H. pylori Neg patients. E. Trichotomic analysis of Akkermansia muciniphila between H. pylori Pos and H. pyloriNeg patients.
Figure 4. Gut microbiome composition for H. pylori Pos and H. pylori Neg patients in lung cohort. Alpha diversity of H. pylori Pos and H. pylori Neg NSCLC patients (n = 28). The bold line represents the median. The bottom and top hinges correspond to the first and third quartiles (the 25th and 75th percentiles). The top whisker extends from the hinge to the largest value no further than 1.5 * interquartile range from the hinge. B. Beta diversity for 28 NSCLC patients stratified by H. pylori seropositivity. C. Differential abundance analysis using LEfSe stratified by H. pylori status. Only species were displayed. Note that the presence of each bacterium on the LEfSe denotes statistical significance (p < .05). D. Relative abundance of Akkermansia muciniphila between H. pylori Pos and H. pylori Neg patients. E. Trichotomic analysis of Akkermansia muciniphila between H. pylori Pos and H. pyloriNeg patients.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. 10.1016/S0022-2836(05)80360-2 · doi:10.1016/s0022-2836(05)80360-2 · Paper page

Cited by

See all 34

Metadata

Authors
Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., Mihalcioiu, C., Watson, I., Bouin, M., Miller, W., Hudson, M., Wong, M. K., Pezo, R. C., Turcotte, S., Bélanger, K., Jamal, R., Oster, P., Velin, D., Richard, C., Messaoudene, M., Elkrief, A., & Routy, B.
Affiliations
  • Université de Lille (FR)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • McGill University Health Centre (CA)
  • Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM)
  • Institut du cancer Rosalind & Morris Goodman (CA)
  • Centre Hospitalier de l’Université de Montréal
  • Jewish General Hospital (CA)
  • Sunnybrook Health Science Centre (CA)
  • Centre Hospitalier Universitaire Vaudois (CH)
Corresponding author
Routy, Bertrand
Venue
OncoImmunology
Published
2022-07-07
Volume
11
Issue
1
Pages
2096535-2096535
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W4284674170
Cited by
34
References
41
Citations by year
2026: 8 · 2025: 8 · 2024: 11 · 2023: 7
FWCI
2.72
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by-nc)
  • IRIS (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Institut du Cancer de Montréal
  • Terry Fox Institute
  • Nuovo-Soldati foundation for cancer research
  • Fonds de Recherche du Québec FRQS
  • Canadian Institutes of Health Research
  • Royal College of Surgeons and Physicians of Canada
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Helicobacter pylori, seropositivity, melanoma, immune checkpoint inhibitors, overall survival, fecal microbiota, gut microbiota, non-small cell lung cancer, microbiome diversity, prognostic factors, immunotherapy response, Helicobacter pylori eradication
MeSH terms
Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Melanoma, Syndrome, Helicobacter pylori, Helicobacter Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1080/2162402x.2022.2096535
The paper
Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., Mihalcioiu, C., Watson, I., Bouin, M., Miller, W., Hudson, M., Wong, M. K., Pezo, R. C., Turcotte, S., Bélanger, K., . . . Routy, B. (2022). Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors. OncoImmunology. https://doi.org/10.1080/2162402x.2022.2096535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.